Czech National Bank Purchases 17,373 Shares of AbbVie Inc. $ABBV

Czech National Bank raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 466,032 shares of the company’s stock after purchasing an additional 17,373 shares during the period. AbbVie makes up approximately 0.7% of Czech National Bank’s investment portfolio, making the stock its 19th biggest position. Czech National Bank’s holdings in AbbVie were worth $106,484,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of AbbVie by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares in the last quarter. Norges Bank acquired a new stake in AbbVie in the second quarter valued at about $4,288,200,000. Legal & General Group Plc boosted its stake in AbbVie by 4.3% in the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after buying an additional 493,420 shares in the last quarter. Wellington Management Group LLP grew its position in AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares during the last quarter. Finally, Amundi grew its position in AbbVie by 15.6% in the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after acquiring an additional 1,414,621 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a multi‑year partnership with Major League Baseball to expand its “Striking Out Cancer” program nationally — a high‑profile marketing and corporate‑responsibility move that should boost brand visibility and patient/public engagement without near‑term material costs. AbbVie Named Official Pharmaceutical Partner of Major League Baseball
• Positive Sentiment: Analysts and value investors are re‑examining ABBV after recent share weakness; one write‑up frames the pullback as a potential buying opportunity based on long‑term fundamentals and pipeline prospects, which can attract bargain hunters. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?
• Positive Sentiment: AbbVie’s psychiatry pipeline expansion (acquisition of bretisilocin) keeps the company positioned in fast‑growing neuropsychiatric markets; the deal supports longer‑term revenue diversification beyond core immunology and oncology franchises. Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026?
• Neutral Sentiment: Investor attention and search interest in ABBV have spiked, which can increase short‑term volatility but doesn’t signal direction on its own. Investors Heavily Search AbbVie Inc. (ABBV)
• Neutral Sentiment: Related sector financing (e.g., Gilgamesh Pharma’s Series A) signals investor appetite for neuropsychiatric assets but is peripheral to AbbVie’s near‑term earnings. Gilgamesh Pharma Closes Oversubscribed $60 Million Series A
• Negative Sentiment: Competitive dynamics: analysts highlight that rivals (notably Eli Lilly) are seeing explosive growth from obesity medicines, whereas AbbVie’s near‑term growth remains concentrated in Skyrizi and Rinvoq—this relative growth gap could limit upside and keep valuation under pressure. LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?

AbbVie Trading Up 0.8%

NYSE:ABBV opened at $206.85 on Thursday. The stock has a market cap of $365.74 billion, a P/E ratio of 87.65, a price-to-earnings-growth ratio of 0.71 and a beta of 0.34. The stock’s 50-day moving average is $222.17 and its 200-day moving average is $224.62. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same quarter last year, the business earned $2.16 EPS. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is 293.22%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ABBV shares. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Evercore decreased their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Piper Sandler upped their price objective on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. William Blair restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $253.15.

Insiders Place Their Bets

In related news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is currently owned by insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.